Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
小说性非肽类GL
P-1激动剂,包括它们的制药组合物,使用非肽类GL
P-1激动剂制备制药组合物的方法以及治疗和/或预防人类GL
P-1受体激活有益的疾病和疾病的方法,特别是代谢紊乱,如IGT,1型糖尿病,2型糖尿病和肥胖症。